CD44 SNP rs187115: A novel biomarker signature that predicts survival in resectable pancreatic ductal adenocarcinoma.
<h4>Purpose</h4> <p>Although pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor, like other common cancers, it displays a wide range of biology. However, at present, there are no reliable tests to predict patients’ cancer-specific outcomes and guide personalized treatme...
Autors principals: | Stracquadanio, G, Vrugt, B, Flury, R, Schraml, P, Würl, P, Müller, T, Knippschild, U, Henne-Bruns, D, Breitenstein, S, Clavien, P, Graf, R, Bond, G, Grochola, L |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
American Association for Cancer Research
2016
|
Ítems similars
-
MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
per: Grochola, L, et al.
Publicat: (2010) -
Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.
per: Vazquez, A, et al.
Publicat: (2010) -
Cough induced rib fracture, rupture of the diaphragm and abdominal herniation
per: Wurl Peter, et al.
Publicat: (2006-11-01) -
Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival.
per: Grochola, L, et al.
Publicat: (2009) -
A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma.
per: Yee, K, et al.
Publicat: (2012)